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We aimed to describe the functional changes of Sertoli cells, based on the measurement of serum anti-Mu¨llerian hormone (AMH)
and inhibin B during treatment with GnRHa and after its withdrawal in boys with central precocious puberty. Six boys aged 0.8 to
5.5 yr were included. AMHwas low at diagnosis in patients >1 yr but within the normal range in younger patients. AMH increased
to normal prepubertal levels during treatment. After GnRHa withdrawal, AMH declined concomitantly with the rise in serum
testosterone. At diagnosis, inhibin B was elevated and decreased throughout therapy, remaining in the upper normal prepubertal
range. In patients with testicular volume above 4mLAMHremained higher in spite of suppressed FSH. After treatment withdrawal,
inhibin B rose towards normal pubertal levels. In conclusion, AMHdid not decrease in patients <1 yr reflecting the lack of androgen
receptor expression in Sertoli cells in early infancy. Serum inhibin B might result from the contribution of two sources: the mass of
Sertoli cells and the stimulation exerted by FSH. Sertoli cell markers might provide additional tools for the diagnosis and treatment
followup of boys with central precocious puberty.
1. Introduction
Precocious puberty in boys is defined as the appearance of the
initial signs of sexual maturation at an age that is more than
2–2.5 SD below the population mean, which is 9 yr for boys
[1]. Precocious puberty can be gonadotropin dependent due
to the early activation of pulsatile gonadotropin secretion or
independent of gonadotropins, as is the case with testotox-
icosis or Leydig cell tumours [2]. The aetiology of an early
activation of pulsatile gonadotropin secretion may be sec-
ondary to an organic lesionwithin the central nervous system
(hydrocephaly, tumours, meningitis, etc.) or due to activating
mutations of the genes encoding kisspeptin [3] or its receptor
GPR54 [4]. However, in many cases the cause that triggers
the onset of puberty cannot be identified. Gonadotropin-
dependent precocious puberty is more prevalent in girls;
nevertheless, the proportion of cases of precocious puberty
secondary to organic lesions is higher in boys [2].
Gonadotropin-releasing hormone analogues (GnRHa) is
the treatment of choice for gonadotropin-dependent preco-
cious puberty of central origin. Therapy induces a reversible
pituitary desensitization ofGnRHreceptors, thus suppressing
the production of gonadotropins and subsequently that of
sex steroids. This slows pubertal progression and decreases
the rate of linear growth and skeletal maturation. Slowing
the advancement of bone age is the primary goal of GnRHa
therapy in order to improve final height [1, 2].
Monitoring treatment effectiveness during GnRHa ther-
apy resides inmultiple items. Growth velocity, secondary sex-
ual characteristics, and bonematuration are the main clinical
parameters. Serum LH and FSH measured by ultrasensitive
assays are used for the assessment of pituitary desensitization
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Table 1: Characteristics of boys with central precocious puberty included in this study.
Age at
diagnosis
(years)
Bone age at
diagnosis
(years)
Peak LH at
diagnosis (U/L)
Peak FSH at
diagnosis (U/L) Etiology
Age at GnRHa
start (years)
Age at GnRHa
end (years)
Patient 1 5.5 8.5 35.30 2.10 Idiopathic 5.6 8.9
Patient 2 4.3 8.5 6.90 0.70 Hypothalamic hamartoma 4.8 10.3
Patient 3 4.3 10.5 13.40 3.10 Hypothalamic hamartoma 4.3 9.8
Patient 4 1.7 3.6 37.00 2.30 Hypothalamic hamartoma 2.0 10.7
Patient 5 1.0 1.3 32.90 7.40 Idiopathic 2.2 N.A
Patient 6 0.8 2.0 84.90 1.70 Idiopathic 1.1 10.0
N.A: not applicable.
[5, 6], and serum testosterone levels are used to monitor
testicular response to treatment.
Measurement of testicular volume is clinically utilized
for the assessment of pubertal development in boys [7]; the
increase in testicular volume beyond 4mL is typically used
to define the onset of puberty, either normal or precocious.
The initial increase in testicular volume is due to Sertoli cell
proliferation induced by FSH. Subsequently, testosterone pro-
vokes Sertoli cell maturation—characterized by Sertoli cell
proliferation arrest—and triggers pubertal spermatogenesis
in the seminiferous tubules, which mainly accounts for the
dramatic enlargement of testis size to 15–25mL [8]. Other
early signs of pubertal Sertoli cell maturation, which occur
even before serum testosterone rises, are the changes in serum
levels of two specific Sertoli cell products: the decrease in anti-
Mu¨llerian hormone (AMH) [9–11] and the increase in inhibin
B [12–14].
In the present study, our primary objective was to assess
functional changes in Sertoli cells, based on themeasurement
of serum AMH and inhibin B during treatment with GnRHa
and after its withdrawal in boys with central precocious
puberty.
2. Methods
2.1. Patients. Boys diagnosedwith central precocious puberty
at the Division of Endocrinology of the Hospital de Nin˜os
Ricardo Gutie´rrez, a tertiary paediatric public hospital in the
city of Buenos Aires, Argentina, and treated with GnRHa
between 1995 and 2013 were included in the study. Patients
were excluded if history chart or results of serum hormone
determinations (FSH, LH, testosterone, and AMH) were not
complete or available. A clinical examination was performed
at each visit to assess pubertal stage according toMarshall and
Tanner [7] and to determine testicular volume by comparison
with Prader’s orchidometer [15]. The mean of the volume of
both testes was reported. LH, FSH, testosterone, inhibin B,
and AMH serum concentrations were assessed periodically
before, throughout, and after treatment with GnRHa. The
study was approved by the institutional review board. The
need for informed consent was waivered owing to the obser-
vational design of the study, in which most of the procedures
followed the standard care of patients with central precocious
puberty, and because results of serum AMH and inhibin B
levels were not considered for decision making.
2.2. Hormone Assays. AMH was determined using an
ultrasensitive enzyme linked immunoassay specific for
human AMH (Immunotech, Beckman-Coulter Co., Mar-
seilles, France), following the manufacturer’s instructions as
previously published [16]. The analytical sensitivity of the
assay, defined as the lowest AMH concentration significantly
different from the calibrator zero, was 2.3 pmol/L. Intra- and
interassay coefficients of variation were, respectively, 10.5%
and 9.4% for a serumAMH concentration of 700 pmol/L and
11.1% and 12.8% for a serumAMH concentration of 7 pmol/L.
Reference values were taken from our own data [16].
Serum inhibin B was measured using two-site enzyme-
linked immunosorbent assays (Oxford Bio-Innovation Ltd,
Oxon, UK) as previously described. Recombinant inhibin B
(Genentech, San Francisco, CA, USA) was used as standard.
The assay sensitivity was 15 pg/mL. Intra- and interassay coef-
ficients of variation were below 10% for all assays. Reference
values were taken from our own data [12].
Serum FSH and LH were measured by time-resolved
immunofluorometric assays (IFMA, DELFIA; PerkinElmer,
Inc. by Wallac Oy, Turku, Finland). The functional sensitiv-
ities were 0.05 and 0.10 IU/L, according to the 2nd WHO IS
80/552 for LH and IRP 94/632 for FSH, respectively. Intra-
and interassay coefficients of variation for IFMA method
were ≤3.2 and ≤7.3% for LH and ≤2.3 and ≤5.2% for FSH, as
previously published [17].
2.3. Statistics. Hormone concentrations below the limit of
the assay detection were assigned a concentration equivalent
to the minimum detectable value in the respective assay.
Data are expressed as median and range. Multiple regression
analysis was performed to assess the association between
serum inhibin B levels and testis volume during followup
after GnRHa treatment. The level of significance was set at
𝑃 < 0.05. Statistical analyseswere performedusingGraphPad
Prism version 5.01 for Windows (GraphPad Software, San
Diego, CA, USA) and IBM SPSS Statistics (IBMCorporation,
Somers, NY, USA).
3. Results
Six boys with central precocious puberty were included in
the study (Table 1). Their median age at diagnosis was 3 years
(range 0.8–5.5) with a bone age of 8.5 years (range 1.25–10.5).
International Journal of Endocrinology 3
0
5
10
15
20
25
30
6.7 4.3 4.1 4.2 5.0 9.8 21.0
Months under
GnRHa
Months after GnRHa
withdrawal
Before GnRHa
Te
sti
s v
ol
um
e (
m
L)
(2.5–9.0) (3.1–8.0) (3.0–7.5) (2.6–7.2) (3.0–7.0) (9.0–17.5) (18.8–23.3)
6–24<6 >24 6–24<6 >24
(a)
0
2
4
6
8
10
12
1.75 0.35 0.14 0.16 1.04 1.76 1.95
FS
H
 (I
U
/L
)
Months under
GnRHa
Months after GnRHa
withdrawal
Before GnRHa
6–24 6–24
(0.61–5.36) (0.14–1.00) (0.10–0.28) (0.10–0.46) (0.99–1.08) (0.79–10.50) (1.37–2.36)
<6 >24 <6 >24
(b)
0
2
4
6
8
10
12
3.75 0.76 0.29 0.18 0.40 1.30 2.91
LH
 (I
U
/L
)
Months under
GnRHa
Months after GnRHa
withdrawal
Before GnRHa
6–24 6–24
(0.88–11.20)(0.24–7.05) (0.17–1.41) (0.05–0.45) (0.17–0.63) (0.63–7.60) (1.75–4.07)
<6 >24<6 >24
(c)
0
500
1000
1500
419 17 10 13 43 237 381
Te
sto
ste
ro
ne
 (n
g/
dL
)
Months under
GnRHa
Months after GnRHa
withdrawal
Before GnRHa
6–24 6–24
(12–878) (10–34) (10–34) (10–26) (10–176) (44–832) (262–500)
<6 >24 <6 >24
(d)
0
200
400
600
800
1000
1200
118 219 624 683 746 82 54
A
M
H
 (p
m
ol
/L
)
(50–645) (170–578) (495–1053) (305–809) (727–765) (70–573) (19–89)
Months under
GnRHa
Months after GnRHa
withdrawal
Before GnRHa
6–24 6–24
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
<6 >24 <6 >24
(e)
0
100
200
300
400
500
600
400 384 244 168 216 262 195
In
hi
bi
n 
B 
(p
g/
m
L)
Months under
GnRHa
Months after GnRHa
withdrawal
Before
GnRHa
6–24 6–24
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
(212–561) (335–434) (71–261) (98–213) (137–295) (104–395) (179–210)
<6 >24 <6 >24
(f)
Figure 1: Testicular volume and hormone levels of boys with central precocious puberty before, during, and after withdrawal of GnRH
analogue treatment. Medians and ranges are shown on the top of each figure for each time point.
In three cases, precocious puberty was due to a hypothalamic
hamartoma and in the other three it was idiopathic. Patients
were treated with triptorelin acetate every 28 days at a 110–
190𝜇g/kg dose. GnRHa treatment was stopped at a median
age of 10.1 (range 8.9–10.7). Patient 5 was still in treatment at
the moment of the study.
At diagnosis, testicular volume was between 2 and
9mL (Figure 1(a)), FSH was 1.75 IU/L (range 0.61–5.36)
(Figure 1(b)), median basal LH was 3.75 IU/L (range 0.88–
11.20) (Figure 1(c)), and testosteronewas 419 ng/dL (range 12–
878) (Figure 1(d)). Median peak LH after an acute GnRH test
was 35.30 IU/L (range 6.90–84.90) (Table 1). Serum AMH
was low in the four patients older than 1 year (median
67 pmol/L, range 50–165) but was within the normal range
in the two patients aged ≤1 year (645 and 475 pmol/L)
(Figure 1(e)). Interestingly, in Patient 5, whowas diagnosed at
12 months of age, AMH (475 pmol/L) was within the normal
prepubertal range.Due to social difficultiesGnRHa treatment
could not be started until the age of 2.2 yr when serum AMH
had decreased to 131 pmol/L. Before treatment serum inhibin
B was elevated (400 pg/mL, range 212–560) (Figure 1(f)).
Throughout treatment with GnRHa, testis volume
decreased but remained moderately above the normal
prepubertal size in most patients (Figure 1(a)). As expected,
serum gonadotropins and testosterone showed a progressive
decrement toward normal prepubertal levels and remained
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Figure 2: Correlation between testicular volume and serum inhibin
B levels in boys with central precocious puberty during GnRH
analogue treatment.
so until GnRHa withdrawal, when they increased again
to pubertal levels (Figures 1(b)–1(d)). AMH increased
progressively and remained within the normal prepubertal
range during the whole treatment (Figure 1(e)). After GnRHa
withdrawal, AMHprogressively declined concomitantly with
the rise in serum testosterone, as in normal puberty [16, 18].
Serum inhibin B levels decreased moderately through-
out GnRHa therapy attaining its nadir after 24 months
of treatment. Thereafter, they remained in the upper half
of normal prepubertal age range (Figure 1(f)). A multiple
regression analysis using patient and testis volume as the
independent variables and inhibin B levels as the dependent
variable showed a significant positive correlation between
testicular volume and serum inhibin B levels during treat-
ment (𝑟 = 0.561 𝑃 < 0.001) (Figure 2). Interestingly, dur-
ing GnRHa treatment the lowest levels of inhibin B were
observed in Patients 1, 2, and 6, in whom testicular vol-
ume achieved normal prepubertal range, whereas inhibin
B remained higher in Patients 3 and 4, who maintained
testicular volume above 4mL in spite of suppressed FSH
levels. After treatment withdrawal, inhibin B rose toward
normal pubertal levels concomitantly with the reactivation of
the gonadotropin axis.
4. Discussion
By means of serum AMH and inhibin B assessment, this
work depicts the functional changes occurring in the sem-
iniferous tubule compartment—and especially in Sertoli
cells—in response to GnRHa treatment in boys with central
precocious puberty. Our results show that the abnormally
early maturation process suffered by Sertoli cells in boys with
precocious puberty in response to testosterone is reversible
when patients are efficaciously treated with GnRHa, most
probably reflecting the decrease to prepubertal levels in
intratesticular testosterone concentration. On the contrary,
inhibin B levels do not always decrease to prepubertal values
although FSH secretion is also curtailed by GnRH admin-
istration, most probably indicating that the increased mass
of Sertoli cells is not fully reverted and continues secreting
inhibin B independently of FSH stimulation.
Most of our patients had low serum AMH levels for
their chronological age when central precocious puberty was
diagnosed, showing the well-known inhibition exerted by
androgens on Sertoli cell AMH production. The inhibitory
action of androgens predominates over the stimulatory effect
of FSH on Sertoli cell AMH expression [19, 20]. Conversely,
FSH action on Sertoli cells is reflected by the initial increase
in testicular volume and serum inhibin B. AMH downreg-
ulation and inhibin B upregulation also reflect the entry into
meiosis of germ cells. In fact, the onset ofmeiosis is associated
with a further decline in AMH expression, independently of
testosterone, during pubertal development [21]. Concerning
inhibin B production by the testis, the immature Sertoli cell
synthesizes the 𝛼/𝛽B dimer, whereas the pubertal Sertoli cell
essentially produces the 𝛼 subunit under FSH control; the
𝛽B subunit expression is mainly regulated by local factors
produced by meiotic germ cells [22].
During GnRHa treatment AMH attained normal pre-
pubertal levels, as previously described [9], which accounts
for the usefulness of Sertoli cell serum markers to monitor
the efficacy of GnRHa treatment in order to produce a
sufficient decrease in gonadotropin production so as to lower
intratesticular androgen action to prepubertal levels. The
functional maturation of Sertoli cells induced at pubertal
onset, reflected in AMH downregulation by androgens,
seems to be a completely reversible processwhen treated soon
before its establishment, as was the case in Patients 1–4 of our
series and in previously published cases [9]. On the contrary,
Sertoli cells do not revert to a fully immature state if the
action of intratesticular androgens has persisted for years or
decades, as shown in adult males receiving GnRHa treatment
for prostate cancer [23].
A noteworthy observation in our study was that serum
AMH remained in the normal prepubertal range in patients
with central precocious puberty diagnosed within the first
year of life, suggesting that the elevated androgen levels were
unable to inhibit AMHproduction in young infants. Interest-
ingly, testicular volume also remained within the prepubertal
range in these patients, probably indicating that pubertal
spermatogenesis had not been triggered. These observations
are in line with the recent description that Sertoli cells are
physiologically insensitive to the direct action of androgens
in the first year after birth because they do not express the
androgen receptor until later in life [24–26]. Concordantly, in
our Patient 5, AMHwas at prepubertal levels when diagnosed
at 12 months of age and, because treatment could not be
immediately installed, serum AMH decreased to pubertal
levels at age of 2.2 years, supporting the concept of a gradual
increase in androgen receptor expression within the Sertoli
cell population.
At diagnosis, serum inhibin B levels were elevated in
all patients, resembling what occurs under normal pubertal
development at Tanner stages II to III. Treatment with
GnRHa resulted in a reduction in serum inhibin B levels
in all patients. However, the magnitude of this decrement
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was variable amongst patients. In some patients, inhibin B
remained in the upper normal range during treatment, in
correlation with the persistence of moderately elevated testis
volume, despite suppressed FSH secretion. This probably
reflects that the increased mass of Sertoli cells induced
by elevated FSH until diagnosis is not fully restored to
the prepubertal stage and continues secreting inhibin B,
independently of FSH stimulation [14]. We believe that
serum levels of inhibin B reflects the addition of two pools:
a basal one related to the mass effect of the Sertoli cell
population independent of the gonadotropins and a second
one related to the stimulation exerted by FSH. The mass
effect is evidenced by the observation that testicular volume
remains over the normal prepubertal volume in a subset of
patients under GnRHa treatment, concomitantly with higher
serum inhibin B levels. It could be argued that these elevated
serum inhibin B levels result from an insufficient inhibition
of the gonadotropin axis with GnRHa treatment. This seems
unlikely, however, since serum levels of LH and testosterone
were efficaciously suppressed and resulted in a normalization
of serum AMH.
In summary, we describe the different functional changes
observed in Sertoli cells of boys with central precocious
puberty according to their age at the moment of diagnosis.
Sertoli cell markers provide additional tools to diagnose
central precocious puberty in boys older than 1 year and
to monitor GnRHa treatment efficacy. The observation that
serum AMH does not decrease in patients below 1 year
confirms the lack of androgen receptor expression in Sertoli
cells in early infancy. Finally, we hypothesize that serum levels
of inhibin B represent the addition of two pools, one related
to the stimulation exerted by gonadotropins and another one
to the mass effect of the Sertoli cell population independent
of the gonadotropins.
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